Acumen Pharmaceuticals, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ABOS Company Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
ABOS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ABOS Smart Score
Score Breakdown
ABOS Company Description
Show More
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ABOS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ABOS's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on ABOS's company Twitter account
WallStreetBets
Number of mentions of ABOS in WallStreetBets Daily Discussion
ABOS News
Recent insights relating to ABOS
CNBC Recommendations
Recent picks made for ABOS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ABOS
Corporate Flights
Flights by private jets registered to ABOS
Our Analysis